Agoracom Blog Home

Posts Tagged ‘Cannabis’

Mota Ventures $MOTA.ca Talks Strategy on Mushrooms and CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:30 AM on Thursday, May 21st, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

Results of the 2019 calendar year audit of Nature’s Exclusive:

  • Revenue of Cdn$29,034,000
  • Net income of $3,505,000
  • Achieved a margin of over 12%

VANCOUVER, BC / ACCESSWIRE / May 21, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) would like to thank all shareholders and investors for attending yesterday’s investor call. The main items addressed on the call were the completion of 2019 audit of the Nature’s Exclusive brand and the expansion of business in the natural health products sector through the proposed acquisition of Verrian.

The 2019 financial results for the Nature’s Exclusive brand is a strong indicator of the power of the Company’s eCommerce business model. This growth continued into 2020. For the months January through April 2020, the Company has generated revenue of Cdn$13,968,000 with related expenses of Cdn$13,514,000. Revenue has increased 188% for this time period over the same period during 2019. The Company’s customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature’s Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.

As a leading business in the natural health products sector, we’ve been aggressively looking to expand our offering into growing segments of the market. Through this process, we identified psychedelic medicine as a unique opportunity, due to the overwhelming momentum of the sector and the incredible health benefits that can be obtained through derivative products.

The Company has come to terms to acquire Verrian, a leading company in the psychedelic medicine sector. Verrian owns and operates an established 110,000 square-foot pharmaceutical manufacturing facility in Germany that holds EU-GMP, ISO 14001, and narcotics manufacturing licenses. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Beyond the importance of this manufacturing asset, Verrian’s product commercialization process is already underway. The business has invested over Cdn$2,000,000 in clinical trials with two studies that are ongoing. These studies combined with our manufacturing abilities will uniquely prepare us to go-to-market once approval is granted.

Verrian’s product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs. While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids. For those individuals who have suffered a loss due to one’s addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Mota is even more meaningful. In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients. According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42,000,000,000 in 2020, with over 15,000 private treatment facilities and growing.

“Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products. While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian. I look forward to working with Verrian’s incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine,” stated Ryan Hoggan, CEO of the Company.

Completion of the acquisition of Verrian remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation. For further information regarding the proposed acquisition, readers are encouraged to review the Company’s news release of May 19, 2020.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Mota Schedules Conference Call to Discuss Recent Announcements $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:20 PM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ)(OTC:PEMTF) (the “Company) a direct to consumer provider of a wide range of CBD products globally, is pleased to announce it will be hosting an investor conference call on Wednesday, May 20, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss recent announcements.

The call will be held on May 20, at 1:15 pm Pacific Time.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Mota Ventures $MOTA.ca Announces Completion Of Audit For Nature’s Exclusive Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:31 AM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC, CANADA / ACCESSWIRE / May 19, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce completion of an audit of the financial results of its Nature’s Exclusive brand through the twelve-months ended December 31, 2019.

  • 2019 audited financial results:
  • Revenue of Cdn$29,034,000
  • Associated expenses of Cdn$25,530,000
  • Net income of Cdn $3,505,000

“Completion of the 2019 audit is a culmination of an extensive team effort, and represents a significant milestone in the validation of our eCommerce business. The 2019 figures, where we achieved over 12% net income, provides us with a benchmark from which to measure our success in the 2020 fiscal year as we continue to build on the strong results generated by Unified,” noted Ryan Hoggan, Chief Executive Officer of the Company.

Throughout the 2019 calendar year, the Nature’s Exclusive brand was operated as a separate business segment of Unified Funding, LLC (“Unified“). The Company completed the acquisition of the brand, and the associated business line, on January 17, 2020. The audit was completed on carve-out financial statements of Unified, which present the standalone financial results of the brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada average annual exchange rate of US$1.00:Cdn$1.3269 for 2019.

The Company also announces that it has reached an agreement with Unified to amend the thresholds necessary for Unified to earn a bonus based on the financial results generated by the Nature’s Exclusive brand in the 2020 calendar year. Unified is entitled to earn a bonus payment based on the terms of the original transaction in which Mota acquired control of the brand, and the associated business line.

Under the terms of the amendment, Unified will continue to be entitled to a one-time bonus payment (the “Bonus Payment“) based on the revenue and profitability of Nature’s Exclusive in the 2020 calendar year. The Bonus Payment will be: (i) US$5,000,000, in the event gross revenue exceeds US$40,000,000 with a profit margin of at least ten percent; (ii) US$10,000,000, in the event gross revenue exceeds US$45,000,000 with a profit margin of at least ten percent; or (iii) US$15,000,000, in the event gross revenue exceeds US$50,000,000. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“) based on an exchange rate of US$1.00 to C$1.30 and the greater of: (i) C$0.80; and (ii) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the last trading day of 2020. Any Bonus Shares issuable by the Company will be subject to the terms of a thirty-six month time release pooling arrangement, with applicable release dates calculated from the date of issuance of the Bonus Shares.

For further information regarding the Bonus Payment, and the acquisition of Nature’s Exclusive, readers are encouraged to review the Company’s news release of January 17, 2020.

“Revising the 2020 performance bonus will help to align our interests with Unified, and ensure they remain incentivized in the development of Nature’s Exclusive in the context of the current market. The brand has demonstrated strong financial results through 2020 to date, in spite of economic volatility and we look forward to continued success leading into the second half of 2020,” commented Ryan Hoggan, Chief Executive Officer of the Company.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

North Bud Farms $NBUD.ca Announces Proposed Terms for Non-Brokered Private Placement of Units $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, May 19th, 2020
  • Intends to complete a non-brokered private placement of units at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million
  • Proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations.

TORONTO, May 19, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of units (each a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million (the “Offering”).

Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share (a “Warrant Share”) for a period of 24 months following the Closing Date (as defined below) at an exercise price equal to: (i) $0.075 if the Warrant is exercised within 12 months of the Closing Date, or (ii) $0.10 if the Warrant is exercised at any other time prior to expiry.

The Company may pay a cash fee or issue compensation securities to certain eligible finders in connection with the proceeds received by the Company from the sale of Units to subscribers introduced to the Company by such eligible finders.

The proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations. Management believes that securing a 12-month cash runway is the most prudent step in attempting to secure the long-term viability of the Company. Failure to meet these capital requirements could force management to proceed with secondary options that may preserve less long-term value for shareholders. Subscription receipts will be held in escrow and released upon the filing of the Company’s 2019 financial statements.  The Offering is expected to close on or around June 1, 2020 (the “Closing Date”).

Anyone who is interested in participating in the current financing may email the Company at: [email protected]
The Offering is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

The Units will be offered: (i) on a private placement basis in all of the provinces and territories of Canada; (ii) in the United States on a private placement basis in reliance on Rule 506(b) of Regulation D or pursuant to other exemptions from the requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and in compliance with applicable United States federal securities laws and any “blue sky” laws or regulations of any state of the United States; and (iii) in such jurisdictions outside of Canada and the United States as determined by the Company on a private placement or equivalent basis.

Participation in the Offering will be open to anyone who qualifies under an accredited investor exemption and to existing shareholders (each an “Existing Shareholder”) of the Company as of the close of business on May 19, 2020 (the “Record Date”) who are eligible to participate in the Offering in reliance on the existing shareholder exemption under Canadian securities laws (the “Existing Shareholder Exemption”).

The aggregate acquisition cost to an Existing Shareholder relying on the Existing Shareholder Exemption cannot exceed $15,000 in any 12-month period, unless such Existing Shareholder has obtained advice regarding the suitability of the investment from a registered investment dealer in that Existing Shareholder’s jurisdiction. Persons who become shareholders of the Company after the Record Date are not permitted to participate in the Offering using the Existing Shareholder Exemption, however other exemptions may still be available.

The Units and any Warrant Shares issued upon the exercise of the Warrants issued in connection with the Offering will be subject to a statutory hold period in Canada of four months and one day following the Closing Date. Additional resale restrictions may apply under the laws of other jurisdictions.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities described herein have not been and will not be registered under the U.S. Securities Act, or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available.

In addition, the Company has resolved to re-price the 26.9M of currently issued and outstanding common share purchase warrants with exercise prices between $0.30/share and $0.40/share and various expiry dates, to a new reduced exercise price equal to $0.10 per share in order to align with the current proposed private placement and to encourage such warrant holders to exercise their warrants.  This reduction of warrant exercise prices is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

Additional Cost Cutting Measures

As of May 15, 2020, all members of senior management have been asked to agree to a 30% reduction in their cash-based compensation for the next four months, and to instead receive Common Shares in lieu.

The Company wishes to advise shareholders that it has successfully renegotiated approximately CDN$1 million in current payables by its subsidiary into a 24-month payment obligation. The restructuring improves the Company’s balance sheet and reduces monthly cash requirements moving forward. While this alleviates certain cash flow requirements, it does not affect the Company’s need to raise a minimum of $1 million of proceeds under the Offering.

Management Cease Trade Order Update

Additionally, the Company provides the following update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.

The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.

The Company continues to work closely with its auditor and expects to file the Required Filings before the end of May 2020.

The Company is providing this status update in accordance with National Policy 12- 203 Management Cease Trade Orders (“NP 12-203“). The Company intends to follow the provisions of the Alternative Information Guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases, for as long as the Company remains in default. The Company confirms as of the date of this news release that there has been no material change in the information contained in the default announcement issued on March 13, 2020 and there is no other material information concerning the affairs of the Company that has not been generally disclosed.

Issuance of Common Shares for Services Rendered

The Company has proceeded with the issuance of 472,222 Common Shares, at an issue price of $0.18 per share, to an arm’s length advisor to the Company. The Common Shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $85,000 cash value of the services rendered to the Company by the advisor.

About North Bud Farms Inc.

NORTHBUD owns and operates, through its subsidiaries, licensed cannabis facilities in Canada, California and Nevada. Bonfire Brands USA, the Company’s U.S. subsidiary, acquired cannabis production facilities in Salinas, California and Reno, Nevada in late 2019. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada facility, located on 3.2 acres of land, was acquired through the acquisition of Nevada Botanical Science, Inc., and includes a world-class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation space which holds medical and adult-use licenses for cultivation, extraction and distribution. Through its Canadian subsidiary, GrowPros MMP Inc., the Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the expected proceeds of the Offering, the completion of the Offering including the timing thereof, the intended use of proceeds from the Offering, the timing of the Company filing the Required Filings and the submission of the Company’s license application to Health Canada. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com. 

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

Mota Ventures $MOTA.ca Enters into Binding Term Sheet to Acquire 110,000 Square Foot European Pharmaceutical Manufacturer of Natural Psilocybin Products $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:47 PM on Saturday, May 16th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 16, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a binding term sheet (the Term Sheet“), dated May 14, 2020, with Verrian Ontario Limited (“Verrian“), pursuant to which it proposes to acquire all of the outstanding share capital of Verrian (the “Transaction“). The Term Sheet replaces the previous preliminary letter of intent entered into with Verrian on May 11, 2020. Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Verrian will operate three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

“Signing this binding term sheet is an important step towards Mota’s goal of becoming a leader in the natural health space. Verrian’s significant investment into its licensing, research, equipment and facilities have made it one of the top psychedelic medicine companies. Mota is poised to capitalize on an emerging industry and will continue to expand its North American and European operations to ensure a strong distribution network is in place once this line of product is approved to go to market,” stated Ryan Hoggan, CEO of the Company.

The binding Term Sheet contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$20,000,000, which will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian. The Consideration Shares will be issued at a deemed price of equivalent to the volume-weighted average closing price of the common shares of the Company in the ten trading days immediately prior to the entering into of definitive documentation in respect of the Transaction.

The Consideration Shares will be subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company will arrange for repayment of existing shareholder loans of Verrian totaling approximately Cdn$1,100,000.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Transaction, an administrative fee of $422,000, payable in common shares of the Company, will be owing to a consultant who assisted with the Transaction.

The Transaction remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approval and the negotiation of definitive documentation, which is expected to include warranties, representations, covenants, terms and conditions which are customary and consistent with industry standards for a transaction of this nature, as a well as a mutual break fee in the event of termination. The Transaction cannot be completed until these conditions have been satisfied.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

The Canadian Securities Exchange has in no way passed upon the merits of the Transaction, and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

People are choosing #cannabis over cocktails because it’s healthier – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:05 PM on Friday, May 15th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

People are choosing cannabis over cocktails because it’s healthier

  • What’s a safer, healthier option to alcohol? That would be cannabis, say 90 per cent of Americans asked about their use of substances last year.
  • The findings seem to reflect that people trying to adopt healthier lifestyles are thinking cannabis could be a better fit than alcohol, suggests an article by Merry Jane.

By Angela Stelmakowich

A healthier lifestyle was among four factors associated with more people consuming weed in 2019 than in 2018. The other three factors include there being less stigma around cannabis, legalization and decriminalization efforts, and pot from legal U.S. states being sold on the black market in states where cannabis is still a no-no.

The National Cannabis Study, released last month by marketing research firm MRI-Simmons, notes the single-year jump in cannabis consumption between 2018 and 2019 was significant. About 22 per cent of surveyed Americans consumed weed at least once in 2019 compared to 16 per cent in 2018. That represents a 38 per cent hike.

Of those who used cannabis in 2019, the survey shows 17 per cent consumed once a month or more, while seven per cent consumed daily.

Cannabis, herbal supplements and vitamins were all up from 2018 to 2019. / Photo: Christopher Furlong/Getty Images Christopher Furlong/Getty Images

While consumption of cannabis, herbal supplements and vitamins were all up from 2018 to 2019, caffeine and alcohol consumption dropped slightly, both by about three per cent.

About 58 per cent of respondents also said that marijuana should be legal, up from 56 per cent in 2018, and almost two-thirds, 64 per cent, over the age of 18 expect marijuana to become legalized in all states within the next five years.

The study used a nationally representative online sample of more than 5,000 respondents.

Source: https://www.thegrowthop.com/cannabis-news/cannabis-continuing-to-mainstream-with-more-americans-using-weed-in-2019

Mota Ventures $MOTA.ca Signs Letter of Intent to Acquire German Leader in Psilocybin Space with a 110,000 Square Foot Manufacturing Facility $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 7:49 AM on Thursday, May 14th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 14, 2020 /Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a letter of intent (the “Letter of Intent“), dated May 11, 2020, with Verrian Ontario Ltd. (“Verrian“), pursuant to which the parties intend to evaluate a potential transaction involving the acquisition of all of the outstanding share capital of Verrian (the “Proposed Transaction“). Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards.

Verrian is composed of three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed:

  • PSI GEN and
  • PSI GEN+

These Psilocybin products are focused on opiate addiction reduction. As Natural Psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to facility & equipment investments outlined above, the company has invested Cdn$2,400,000 worth of clinical trial design development and proprietary formulations into its psilocybin trademarked PSI-GEN formulations, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP & narcotics handling recertification are secured, capabilities will extend to:

  • Specialty Pharma – Custom formulations
  • Psilocybin Refinement & Production – For micro dosing

“I am extremely excited at the opportunity to acquire an established Psychedelic medicine company in Europe. As an innovative company, Mota always seeks to be a leader in the natural health space and we see the psychedelic medicine market becoming a major part of the industry. This acquisition allows us to have first mover advantage in the Psychedelic market, and Mota’s existing distribution network will be ready to capitalize on the opportunity once regulation has been put in place,” stated Ryan Hoggan, CEO of the Company.

The Letter of Intent contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$21,100,000, of which Cdn$20,000,000 will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian, and the balance will be payable in cash to retire certain outstanding shareholder loans due and owing by Verrian. The Consideration Shares will be subject to the terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded.

Readers are cautioned that the Letter of Intent entered into with Verrian does not set forth the final terms of the Proposed Transaction, nor have such terms been finalized. Any consideration offered to acquire Verrian remains subject to the results of ongoing due diligence. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Verrian, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Hollister Biosciences Inc. $HOLL.ca CEO Provides Corporate Update $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 9:27 PM on Wednesday, May 13th, 2020
  • “As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”

VANCOUVER, May 13, 2020  - Hollister Biosciences Inc. (CSE: HOLL, OTC: HSTRF,  FRANKFURT: HOB) (the “Company“, “Hollister Cannabis Co.” or “Hollister“) a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to provide a Corporate Update from CEO, Carl Saling.

“As the country begins to emerge from stay at home orders, we thought it would be prudent to provide our shareholders with an update on our operations and some additional details on our recently announced acquisitions, Alphamind and Venom Extracts.” Said Carl Saling, CEO Hollister. “Integration of the new companies is well underway and continues to run smoothly”

COVID-19 (the “Pandemic”) Update

In many states across the country cannabis was deemed an essential business and Hollister has been able to stay operational in all the states in which it operates.

It has been a challenging environment; however, we have navigated the new environment effectively.  Some cities and counties only allowed curbside pick-up and or delivery of cannabis, while others have closed but others stayed completely open for business using and implementing safety precautions.

Hollister took action to help the communities in which they operate by manufacturing hand sanitizer and donated it to offices and front-line workers. As recognition for our efforts the county of Hollister, California awarded Hollister Cannabis Co. a Certificate of Appreciation for our support.

Today, Hollister’s facilities are operating under social distancing guidelines to ensure the Company’s employees are safe.  The Company has also provided employees with gloves, masks and hand sanitizer to take home.  It is the Company’s first order concern during the pandemic to ensure that employees are operating in a safe and healthy environment and provide them with the tools they need to keep themselves and their families safe.

Hollister Cannabis Co.

Hashbone, the Company’s bubble hash infused pre roll brand, continues to grow and gain new fans daily.  The Company introduced HashBone “Minis” which are 0.5 gram bubble hash infused pre-rolls packaged in a 5 pack. The Company has rolled out Hybrid and Sativa SKU’s now available in select California dispensaries. 

The Company also plans to introduce the HashBone “Wolfie”, which answers the call of the true connoisseur. The HashBone Wolfie is a traditional HashBone coated with full spectrum cannabis oil and rolled in bubble hash.  There is hash on the inside and hash on the outside with full spectrum oil holding them together.  The HashBone Wolfie is currently in the testing phase and estimated to be in the market before the end of May 2020. 

Strategic Alliances with Tommy Chong

Further to the news release dated February 7, 2020, the Company is pleased to disclose the strategic relationship with Tommy Chong is progressing well. Hollister is very close to launching its 1st SKU with Tommy Chong called Tommy Chong’s Cannabis Full Spectrum Elixir comprising a 1:1 ratio – 500mg CBD: 500mg THC.  The product has completed testing, labels are being generated, and the Company expects product launch before the end of May 2020.

Venom Extracts

Venom Extracts (“Venom“) continues to be integrated within Hollister Biosciences operations and the synergies are evident. Plans are underway for expansion of Venom into Hollister’s manufacturing facility in California with engineering and permitting processes underway.  The Company anticipates Venom will be producing in California in Q4 2020.

Throughout the pandemic, Venom products continued to see significant growth in demand which resulted in record revenue for Q1, 2020.  Although these numbers will be disclosed in Hollister’s Q1 report, only a small portion will be included in Hollister’s audited financial statements, as the acquisition closed on March 24, 2020 

AlphaMind

The integration process is underway pursuant to the Company’s recently announced acquisition of AlphaMind (see News release dated April 30, 2020).  The Company believes AlphaMind’s medicinal mushroom based product SKU’s will be complementary to Hollister’s existing product line.  AlphaMind has an agreement in place with an established US based manufacturing partner.  It is the Company’s intention to build out an e-commerce platform to market and distribute AlphaMind’s product line.  AlphaMind is a new entrant in the burgeoning medicinal mushroom sector and is also in the process of developing IP surrounding psilocybin based pharmaceutical treatments.

Future Objectives

The Company believes the pandemic has changed consumer behaviour, possibly in a permanent fashion. 

Hollister believes it can capitalize on this in several ways:

  • The company is looking to accelerate its direct to consumer platform for both the hemp and the cannabis markets.
  • Hollister Biosciences will look to build a centralized ecommerce management system that will streamline the sales and marketing of all Hollister Biosciences non cannabis brands like Rebel Hemp Company & AlphaMind.
  • The Company will continue to evaluate the changing cannabis regulatory landscape to expand operations into new states.
  • The Company will also evaluate new technologies which may be utilized in the Company’s Facilities in the future.
  • Hollister Cannabis Co. is currently in the design phase of expanding its facility to accommodate the Venom brand.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com

CLIENT FEATURE: Hollister $HOLL.ca A Vertically Integrated Cannabis Co With Products In 220 California Dispensaries , JVs & Partnerships With Global Brands $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 4:49 PM on Wednesday, May 13th, 2020

Hollister Highlights Of Current Operations:

  • Hollister’s products are now present in 220 of 600 California dispensaries.
  • Own’s California’s #1 hash infused pre-roll “HashBone”
  • Vision is to capitalize on this success to become the sought after premium brand portfolio of Cannabis across multiple states and Hemp nationwide
  • Major LOI, Joint Ventures and Licensing Agreements Support Proof Of This Vision
  • “Easy Riders” – Milliions Of Global Followers
  • “Tactical Relief” – Veteran Founded, Hemp Based CBD Brand With Nation Wide Members  
  • “Tommy Chong” – Exclusive Manufacture & Distribution Of Tommy Chong’s Cannabis (TM) Full Spectrum Elixir 1:1

“I only partner with the best-in-class companies and I am really pleased to have the Hollister Cannabis Co. bring their amazing Tommy Chong’s Cannabis™ Full Spectrum Elixir to the market for me”. 

– Tommy Chong

2 Highly Accretive Acquisitions

Hollister Biosciences Closes Transformational Acquisition of Rapidly Growing Venom Extracts Adding Over $16.4 Million In 2019 Revenue and $2.5 Million in EBITDA

  • one of Arizona’s premier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products.

HIGHLY ACCRETIVE $20,000,000 ACQUISITION, ADDING OVER CDN$16.4 MILLION OF 2019 REVENUE

  • For the year ended December 31, 2019, management of Venom Extracts reports having generated over CDN$16.4 million in revenue and over CDN$2.5 million in EBITDA from its product line of cannabis concentrates and cartridges. 
  • Venom Extract’s management also reports a strong start to 2020 and is anticipating record Q1 revenue.

Hollister Biosciences Closes Acquisition of AlphaMind Brands Inc.

  • Alphamind Brands is developing a portfolio of certified legal mushroom based natural health products
  • The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.

FULL DISCLOSURE: Hollister Biosciences Inc. is an advertising client of AGORA Internet Relations Corp.

TransCanna $TCAN.ca Takes Major Step Towards Delivery License $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:14 AM on Wednesday, May 13th, 2020
TransCanna (@TransCanna) | Twitter
  • Lyfted Farms, has recently executed a lease on property in Lemoore, California that has received approval for a ‘rezoning’ to ‘Industrial’
  • Zoning designation makes the facility eligible for cannabis delivery, along with distribution, manufacturing, and cultivation activities following the anticipated approval of a Conditional Use Permit and Development Agreement, applications for which are currently being finalized
  • Creating this subsidiary with a focus on delivery, says Blink, is also part of the companies’ strategy to service customers in the current environment and at a time when consumer behaviors are affected by potential store closures and safety measures aimed at avoiding the spread of the coronavirus

Vancouver, British Columbia–(May 13, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Lyfted Farms, has recently executed a lease on property in Lemoore, California that has received approval for a ‘rezoning’ to ‘Industrial.’ The newly approved ‘Industrial’ zoning designation makes the facility eligible for cannabis delivery, along with distribution, manufacturing, and cultivation activities following the anticipated approval of a Conditional Use Permit and Development Agreement, applications for which are currently being finalized.

The company has also filed entity registration documents with the California Secretary of State under the name Lyfted Farmacy Inc., to create a new subsidiary with the intention of this business unit being dedicated to delivery. By doing so, TransCanna gains another important business component to complete the supply chain from grow operations to delivery in the California cannabis market (the largest legal market in the world), which is projected to expand exponentially.

“The city of Lemoore has been a great partner to work with. They have been highly responsive and professional partners, especially in this first step towards setting up a fully operational distribution and delivery hub,” says Bob Blink, TransCanna CEO. “The city has really opened their door to Lyfted Farms and been welcoming of our business.”

Creating this subsidiary with a focus on delivery, says Blink, is also part of the companies’ strategy to service customers in the current environment and at a time when consumer behaviors are affected by potential store closures and safety measures aimed at avoiding the spread of the coronavirus.

“We wanted to make sure that we could get higher-quality products from our facility to our customer’s doors in a safe manner,” says Blink. “Having come from diverse industries and bringing this breadth of knowledge to TransCanna means that our management team will continue looking for opportunities to remain highly responsive to changing market demands, and our customers evolving needs.”

This announcement follows news by the company released last week reporting the companies’ quarterly results and record monthly revenue earnings, and a recent announcement that renowned cannabis and lifestyle brand, Cookies, will carry Lyfted Farms products in select locations.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed company building Cannabis-focused brands for the California lifestyle, through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.